STIC Investments to invest $627 mln in Iljin Materials Proceeds to be used to build Hungarian plant
Translated by Kim So-in 공개 2021-04-23 14:33:58
이 기사는 2021년 04월 23일 07:24 thebell 에 표출된 기사입니다.
Iljin Materials, which produces copper foils for rechargeable batteries and printed circuit boards, will receive as much as 700 billion won ($627 million) from Seoul-based private equity (PE) firm STIC Investments.STIC will inject the money into Iljin Materials' Hungary-based subsidiary IMH Technology to fund the construction of its copper foil production facility there, industry sources said on Wednesday. STIC has recently started its marketing campaign towards institutional investors.
Iljin Materials established its Hungarian subsidiary through its Malaysia-based subsidiary IMM Technology in 2020 to enter the European market. Iljin Materials planned to improve its accessibility through its Hungarian plant given that Europe is the production base of global battery and auto makers. IMM Technology injected 15 billion won at the end of last year to complete the construction within this year.
There are currently only five or six companies in the world that manufacture high-quality copper foil, including Iljin Materials. Iljin Materials had the second largest market share of 9.7% globally in 2019, behind Taiwan-based CCP with 12.9%. SK Group’s affiliate SKC is the third-largest with 7.4%.
Back in 2019, STIC had invested 600 billion won in Iiljin Materials by acquiring convertible bonds issued by IMM Technology. The proceeds were used to expand IMM Technology's plants in Malaysia.
STIC made the previous investment through its Special Situation Fund II, which is also expected to be used for the latest investment along with its co-investment fund.
Once the deal is completed, STIC’s investment in Iljin Material will amount to more than 1 trillion won.
IMM Technology is currently preparing its initial public offering in Korea, mandating Korea Investment & Securities and Shinhan Investment to handle the process. IMM Technology recorded revenue of 150 billion won in 2020, and it is estimated to increase to more than 400 billion won this year. Market insiders expect the company’s valuation to be in the 1 trillion won range. (Reporting by Si-eun Park and Byung-yoon Kim)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [제일약품의 온코닉테라퓨틱 첫 '신약']세번째 P-CAB '자큐보' 2년만에 신약 명맥 잇는다
- 강동그룹, 디아너스CC 품는다
- [제약사 TSR 분석]제일약품, '주가·실적·배당' 3중고 열쇠 '온코닉의 신약'
- (여자)아이들 우기, 'YUQ1' 아이튠즈 앨범차트 10개국 석권
- 박셀바이오, 진행성 간세포암 타깃 'Vax-NK' 특허 출원
- 베니스 비엔날레, 30년만에 두발로 선 '곽훈'의 의미
- [대기업 프로스포츠 전술전략]'모기업발 숙제' 엔씨다이노스, 당분간 긴축 불가피
- 하이브, '민희진 없는' 어도어 경쟁력 입증할까
- SK 오너가 3세 최성환의 '승부수'
- 어느 수집가의 꿈 '이건희 컬렉션'